Sequential acid/reduction response of triblock copolymeric nanomicelles to release camptothecin and toll-like receptor 7/8 agonist for orchestrated chemoimmunotherapy

Xiaoyan Ge1†, Yanyun Hao1†, Hui Li1, Huajun Zhao2, Yang Liu1, Yutong Liu1, Xia Li1, Hongfei Chen1, Jing Zou1, Shiying Zhang1, Lingling Huang1, Gang Shan3 and Zhiyue Zhang1*

Abstract

Background: Immunosuppressive tumor immune microenvironment (TIME) lowers immunotherapy effectiveness. Additionally, low penetration efficiency and unpredictable drug release in tumor areas restrict tumor therapy.

Methods: A triblock copolymeric micelle (NanoPCPT+PIMDQ) was developed to carry the chemotherapeutic drug camptothecin (CPT) and the TLR7/8 agonist 1-(4-(aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c] quinoline-4-amine (IMDQ) to achieve deep tumor penetration and on-demand drug release by responding to acid and reduction stimuli sequentially. The synergistic antitumour efficacy of NanoPCPT+PIMDQ was assessed both in vitro and in vivo.

Results: NanoPCPT+PIMDQ is composed of a hydrophilic PEG(polyethylene glycol) outer layer, an acid-sensitive EPEMA middle layer, and a drug inner core. Upon intratumoral injection, (i) NanoPCPT+PIMDQ first responds to the acidic tumor microenvironment and disintegrates to PIMDQ and PCPT, penetrating deep regions of the tumor; (ii) tumor cells are killed by the released CPT; (iii) DCs are activated by PIMDQ to increase the infiltration of cytotoxic T lymphocyte (CTL); and (iv) both downregulated Foxp3+ Tregs by CPT and repolarized M2 macrophages by PIMDQ can relieve the TIME.

Conclusion: This pH/GSH-responsive triblock polymer-drug conjugate reduces immunosuppression and enhances the infiltration of CTLs by codelivering CPT and IMDQ in a controllable manner, providing a promising platform for synergistic tumor chemoimmunotherapy.

Keywords: Regulatory T cells, Chemoimmunotherapy, pH/GSH sequential response, Triblock copolymeric nanomicelles, TLR7/8 agonist
"nonimmunogenic phenotypes" into "immunogenic phenotypes" tumors could be a viable solution to solve this issue. To improve the response rate of nonimmunogenic tumors (i.e., colorectal cancer) [6], it is urgent to simultaneously reverse the immunosuppressive state and enhance the infiltration of CTLs [7, 8]. CPT, a commonly used chemotherapeutic agent, is reported to inhibit Treg cells by reducing the expression of Forkhead box P3 (Foxp3) [9]. Emerging evidence indicates that IMDQ, as a variant of IMQ (imiquimod), promotes macrophage repolarization and stimulates dendritic cell (DC) maturation in tumors and tumor-draining lymph nodes (TDLNs), enhancing CTL infiltration and therapeutic efficacy [10, 11]. Therefore, combining CPT and IMDQ could reverse the immunosuppressive state (decreasing Treg cells and repolarizing M2 macrophages) and increase CTL infiltration, providing a platform to sensitively nonimmunogenic tumors.

Although promising, their precise delivery requires overcoming multiple barriers to penetrate deeply into tumors and achieve on-demand release, which remains challenging. Focusing on these obstacles, previous studies have reported the strategies of charge inversion [12] and size variation [13], demonstrating favorable deep tumor penetration activity. Additionally, a design with responsiveness to tumor microenvironment stimuli, such as pH and GSH, can be used to control drug release [14–16]. Notably, the GSH concentration inside cancer cells (2–10 × 10−3 M) is remarkably higher than that in normal tissue (2–10 × 10−6 M) [17, 18]. Taking advantage of these properties, a GSH-responsive strategy was adopted here to release drugs in tumor cells and optimize the therapeutic efficacy.

Herein, a cascade-responsive trilayer polymeric micelle (NanoPCT+PIMDQ) was developed to codeliver CPT and TLR7/8 agonist in a controllable manner by sequentially responding to pH/GSH to trigger deep tumor penetration and on-demand release. The design of NanoPCT+PIMDQ is based on a triblock copolymer consisting of a hydrophilic poly(ethylene glycol) (PEG) segment, acid-sensitive poly(2-(N-ethyl-N-propyl amino) ethyl methacrylate) (PEPEMA) chain and hydrophobic drug segment (reduction-responsive CPT) prodrug (PCPT) chain or poly(IMDQ) (PIMDQ) chain), which are obtained by RAFT polymerization. Upon intratumoral injection (i.t.), the protonated PEPEMA becomes a hydrophilic fragment with positive charges and subsequently promotes the decomposition of NanoPCT+PIMDQ into PCPT and PIMDQ, which is beneficial for increasing cellular uptake and tumor penetration. TLR 7/8 is stimulated by PIMDQ to activate DCs, and protumoral M2 macrophages are repolarized to antitumor M1 macrophages. Subsequently, the high GSH concentration in tumor cells triggers CPT release from PCPT, which not only provides anticancer cytotoxic effects but also decreases the expression of Foxp3 in Treg cells. Furthermore, combination with TLR7/8 agonists elicits a robust antitumor CTL response in primary and distal tumors (Scheme 1).

Results and discussion

Synthesis and characterization of polymers

Reversible addition-fragmentation chain transfer (RAFT) polymerization was used to prepare polymers, and the detailed synthetic route is illustrated in Fig. 1. Prior to polymerization, monomers of AA (acyrloyl acetone oxime), EPEMA (2-(N-ethyl-N-propyl amino) ethyl methacrylate), and OH-2S-CPT (reduction-responsive CPT monomer) were successfully synthesized (Additional file 1: Figs. S2–S5). PEG-DCT (polyethylene glycol macro-chain transfer agent) was synthesized and utilized to polymerize EPEMA, yielding the diblock polymer PEG-PEPEMA (Additional file 1: Figs. S6, S7). The degree of polymerization (DP) was calculated to be 47 (Additional file 1: Fig. S7). Subsequently, the triblock polymeric prodrug (PEG-PEPEMA-PCPT) was composited using PEG-PEPEMA as a macro-chain transfer agent (macro-CTA) and 2,2′-azobis(2-methylpropionitrile) (AIBN) as an initiator. The resulting DP was calculated to be 5 (Additional file 1: Fig. S8). Moreover, to obtain the IMDQ-conjugated triblock polymer PEG-PEPEMA-PIMDQ, a two-step reaction was needed. First, the triblock copolymer PEG-PEPEMA-PAA was prepared using PEG-PEPEMA as a micro-CTA and AIBN as an initiator, and the DP was 21 (Additional file 1: Fig. S9). The monomer of AA in PEG-PEPEMA-PAA provided a platform for ligating amino group-containing compounds (i.e., IMDQ). Herein, IMDQ was conjugated to the main chain of the polymer by substituting AA, yielding an IMDQ-conjugated triblock polymer PEG-PEPEMA-PIMDQ (Additional file 1: Fig. S10). The grafting rates of CPT and IMDQ were calculated to be 34.09±0.19%, respectively, by UV–vis measurements (Additional file 1: Figs. S11, S12).

Preparation and characterization of NanoPCT+PIMDQ

The preparation process, pH responsiveness and drug release mechanism of NanoPCT+PIMDQ are illustrated in Fig. 2a. The structure of EPEMA changed to a hydrophilic quaternary amine in the acidic tumor milieu, allowing for charge reversal and dispersion of NanoPCT+PIMDQ. These changes not only enhanced the cellular uptake of the conjugate but also increased drug penetration into tumors. To verify our hypothesis, we studied the effect of pH on the size and morphology of NanoPCT+PIMDQ. As illustrated in Fig. 2b–d,
the hydrodynamic particle size of NanoPCPT + PIMDQ at pH 7.4, 6.5, and 6.0 determined by dynamic light scattering (DLS) was 172.43 ± 9.57 nm, 112.83 ± 6.41 nm, and 52.78 ± 5.41 nm, respectively, with a polydispersity index (PDI) of 0.22 ± 0.00, 0.21 ± 0.01, and 0.76 ± 0.01. Transmission electron microscopy (TEM) images obtained under different pH conditions indicated the pH-induced dissociation of NanoPCPT + PIMDQ. Specifically, the morphology of NanoPCPT + PIMDQ was spherical at pH 7.4 with a size of 100–130 nm, tended to be irregular at pH 6.5, and completely collapsed at pH 6.0, further revealing the pH dependence of its morphology. The count rate, representing the average scattering intensity of samples [19], decreased as the pH decreased, especially at pH 6.0, indicating the disassembly of NanoPCPT + PIMDQ (Fig. 2e). To confirm the charge reversal induced by pH, the zeta potential of NanoPCPT + PIMDQ was investigated at different pH values. The zeta potentials of NanoPCPT + PIMDQ reversed from −5.95 ± 0.87 mV at pH 7.4 to 10.87 ± 0.40 mV at pH 6.5 and 24.53 ± 1.17 mV at pH 6.0 (Fig. 2f).

The release kinetics of free CPT in vitro verified the reduction-sensitive release characteristics of nanomicelles designed to control drug release and avoid the toxicity of chemotherapy to normal cells [20]. The samples were dialyzed against various buffered medium in the absence or presence of dithiothreitol (DTT, 10 mM) to study whether the reduction circumstances influenced the CPT release characteristics of NanoPCPT. Negligible CPT was released from NanoPCPT without DTT, no matter under which pH conditions the samples are. However, free drug was constantly released from NanoPCPT if they were immersed into 10 mM DTT solution under different pH (7.4, 6.5, and 5.5), indicating that the release of
drug is dependent on the reduction condition, not or a little bit dependent on the pH conditions in the tumor microenvironment (Fig. 2g and Additional file 1: Fig. S13). Altogether, the combined results revealed that NanoPCPT+PIMDQ exhibited sequential pH/GSH responsiveness, laying the groundwork for our subsequent research.

In vitro cellular uptake and cytotoxicity of nanomicelles
Although CPT has an excellent curative effect, its clinical application is limited due to its low water solubility and high toxicity [21]. Traditional nano-formulations can effectively improve the in vivo pharmacokinetics of CPT, but the physical encapsulation of CPT will still cause damage to the body due to quick leakage in systemic circulation [22]. Covalent ligation to polymeric carriers might offer chemically better-defined alternatives to physical encapsulation technology. Studies have shown that the positive charge of nanomedicine is beneficial to cellular uptake [23]. To evaluate the effects of various pH levels on the cellular uptake of nanomicelles, 5(6)-TAMRA cadaverine (Rho) was used to label nanomicelles, yielding NanoRho. When incubated with CT26 cells at pH = 6.5, NanoRho showed a higher mean fluorescence intensity (MFI) than that at pH = 7.4 (*p < 0.05). This result was attributed to the charge reversal from negative to positive of NanoRho at pH 6.5 (Fig. 3a), which was beneficial to enhance the uptake by tumor cells. To evaluate the tumor penetration ability of NanoPCPT+PIMDQ by 3D multicellular spheroids (MCSs) of CT26 cells, cy5.5 was chosen instead of CPT or IMDQ to label triblock polymeric micelles, yielding Nano\textsuperscript{cy5.5}. Confocal laser scanning microscopy (CLSM) showed that more Nano\textsuperscript{cy5.5} penetrated the interior zone of MCSs at pH 6.5 after 6 h of incubation than at pH 7.4 (Fig. 3b), which was related to the charge...
reversal and gradual dispersion of Nano_{PCPT+PIMDQ} in the acidic tumor microenvironment.

The achievement of charge reversal from negative to positive in the nanomicelles was merely one of the requirements for their efficacy. Subsequently, the cytotoxicity of Nano_{blank polymer} against CT26 cells was assessed by a CCK-8 assay. According to studies, zwitterionic polymers are neutral and thus have low cytotoxicity [24]. Negligible cytotoxicity was observed when the concentration of Nano_{blank polymer} reached 500 μg·mL⁻¹ (Additional file 1: Fig. S14), indicating that it was cytocompatible at a given concentration range. It is worth noting that the concentration of GSH in tumors (2–10 × 10⁻³ M) is reported to be 1000 times higher than that in normal cells (2–10 × 10⁻⁶ M) [25]. The in vitro release of CPT demonstrated the reduction-triggered ability of Nano_{PCPT}. To further confirm the reduction-triggered specific drug release in tumor cells, we investigated the toxicity of free CPT and Nano_{PCPT} to tumor cells (CT26 cells) and normal cells (RAW 264.7 cells) (equal to 3 μM CPT), respectively. As expected, free CPT had equal toxicity to RAW 264.7 cells and CT26 cells, while the viability of macrophages incubated with Nano_{PCPT} was lower than that of CT26 cells (**p < 0.01) (Fig. 3f). Additionally, we explored the toxicity of various concentrations of Nano_{PCPT} against CT26 cells. The cell viability exhibited a dose-dependent effect, and the half-maximal inhibitory concentration of the Nano_{PCPT} group determined to be the CPT-equivalent concentration was 8 μM (Fig. 3c). The results indicated that the carrier, triblock polymer, had high biocompatibility, and Nano_{PCPT} had excellent reduction-induced drug release performance against tumor cells rather than normal cells. Therefore,
compared with other CPT nanocarriers, our carrier could be taken up by cells at tumor sites and had a powerful specific killing effect on tumor cells.

In vitro immune stimulation evaluation

The ability of NanoPIMDQ to activate bone marrow-derived dendritic cells (BMDCs), which are the most effective antigen-presenting cells, was determined by activation assays. For this purpose, either IMDQ or NanoPIMDQ was pulsed with BMDCs, and the extent of DC activation was quantified by flow cytometric measurement of the surface expression of MHC-II and the costimulatory molecules CD80, CD86, and CD40. The intracellular uptake results (Fig. 3d and Additional file 1: Fig. S15) indicated that Rho had a stronger fluorescent signal than NanoPIMDQ after a short period of incubation. The fluorescence of NanoPIMDQ was stronger after 24 h of incubation, whereas that of free Rho was comparatively weaker. That might be due to the fact that free Rho, as a small molecule, was quickly taken up but also quickly pumped out by cells. However, NanoPIMDQ, with a certain size, was gradually more taken up by BMDCs over time, which was conducive to exerting efficacy. Furthermore, BMDCs maturation experiments (Fig. 3e) showed that the upregulation of MHC-II, CD80, CD40, and CD86 was dose-dependent on both the IMDQ and NanoPIMDQ. BMDCs expressed more MHC-II, CD40, and CD86 after treatment with NanoPIMDQ than that treatment of equal IMDQ (5000 nM), mainly due to the difference in cellular uptake levels of IMDQ. Therefore, the results indicated that NanoPIMDQ was still capable of activating DCs, even to a greater extent than the equivalent amount of IMDQ under the experimental conditions.

Tumor-associated macrophages (TAMs) are the major innate immune cells, accounting for approximately 50% of human tumor cells, and thus play vital
roles in antitumor immunotherapy [26]. TAMs assume two opposing phenotypes: antitumoral M1 macrophages and protumoral M2 macrophages. It was reported that TAMs predominantly exhibit M2-type functions promoting intratumoral infiltration of Treg cells, thus contributing to T-cell dysfunction [27]. Therefore, reprogramming M2 macrophages into M1 macrophages could be a promising therapeutic strategy [28, 29]. Here, the effect of free IMDQ and NanoPIMDQ on macrophage repolarization was investigated with IL4-pretreated Raw264.7 cells as a model of protumoral M2 macrophages. CD200R was used to mark M2 macrophages, and iNOS was used to mark M1 macrophages. As shown in Fig. 3g, h, flow cytometric analysis first indicated that Nanoblank polymer (without IMDQ conjugation) did not affect the inflammatory responses, suggesting that these nanomicelles were inherently nonimmunogenic under the experimental conditions. Second, both free IMDQ and NanoPIMDQ treatment induced a dramatic increase in the percentage of M1 macrophages. Briefly, NanoPIMDQ notably reprogrammed M2 macrophages to M1 macrophages to alleviate the immunosuppressive tumor microenvironment. Simultaneously, the percentage of M2 macrophages also slightly increased, which could result from a compensatory immune response. Thus, in our work, IMDQ-ligated nanomicelles are sufficiently capable of activating innate immune responses as well as remodeling macrophages to antitumor M1 phenotypes.

Spatiotemporal biodistribution of Nano55 in vivo

The tissue distribution and tumor retention of triblock copolymeric nanomicelles were evaluated in CT26 tumor-bearing BALB/c mice. Nanomicelles were labeled with cy5.5-amine, injected intratumourally and subsequently imaged using an in vivo imaging system (IVIS) at different time intervals post-injection. I.t. injection of Nano55 yielded a strong and long-term persisting fluorescent signal in the tumor sites compared with that of free Cy5.5. This finding was further confirmed by the increased cy5.5 signal in isolated tumor tissues treated with Nano55 (Fig. 4a–c). To observe the cellular uptake in detail, cancer cells and hepatocytes were isolated separately. Notably, the uptake of Nano55 in tumor cells was higher (****p < 0.0001) than that of free Cy5.5, while it was lower (**p < 0.01) in hepatocytes, according to flow cytometry analysis (Fig. 4d, e). We speculate that the nanomicelles will disintegrate at the tumor site to achieve better tumor penetration, and the disintegration of the drug with a positive charge increased the adsorption of the cells, which induced our nanomicelles to have a longer retention effect after i.t. injection than the free...
In summary, our nanomicelles have a longer retention effect in tumors, which was conducive to minimizing systemic toxicity.

**In vivo antitumor efficacy**

Encouraged by the positive antitumor activity and enhanced immune responses of nanomicelles in vitro, we assessed the therapeutic potential of nanomicelles in vivo. The antitumor efficacy of nanomicelles was evaluated using bilateral CT26 cell-bearing BALB/c mice, where the tumor growing on the right side of the back of BALB/c mice was the primary tumor and that on the left was the distal tumor. When the primary tumor volume reached 50–60 mm³, mice were randomly grouped (n=6) and then treated with PBS, CPT, Nano\textsuperscript{PCPT}, Nano\textsuperscript{PIMDQ}, or Nano\textsuperscript{PCPT+PIMDQ} intratumorally at equivalent doses of CPT (10 mg·kg\(^{-1}\)) and IMDQ (0.5 mg·kg\(^{-1}\)) according to the design schedule shown in Fig. 5a. The tumor volume was monitored using calipers, and the tumors from each treatment group were collected and weighed at the end of the survival study. Nano\textsuperscript{PCPT+PIMDQ} generated the most substantial inhibition in both primary and distant tumors, as shown in Fig. 5b–g, which demonstrated that the combination of CPT-mediated chemotoxicity and Treg cells inhibition, together with TLR agonist-induced immune responses, might inhibit tumor growth synergistically. Images of primary excised tumors indicated that one out of six tumors were completely eradicated after treatment with the combined CPT and IMDQ therapies. In addition, no significant changes in body weight were observed, and the Kaplan–Meier curve displayed improved survival of the mice treated with Nano\textsuperscript{PCPT+PIMDQ}.

To further evaluate the antitumor efficacy of Nano\textsuperscript{PCPT+PIMDQ} in vivo, Ki67, H&E, and TUNEL stains were applied (Fig. 5h). The Ki67 staining images indicated less proliferation in the Nano\textsuperscript{PCPT+PIMDQ} group. The H&E staining images demonstrated that the Nano\textsuperscript{PCPT+PIMDQ} group had extensive cell necrosis. The TUNEL staining images showed the presence of multiple apoptotic cells in the Nano\textsuperscript{PCPT+PIMDQ} group. In summary, compared with the control groups, Nano\textsuperscript{PCPT+PIMDQ} exhibited outstanding therapeutic efficacy and prolonged survival in CT26-bearing mice. There was no obvious tissue damage in the Nano\textsuperscript{PCPT+PIMDQ}-treated group (Additional file 1: Fig. S17).

**In vivo exploration of the antitumor immune mechanism**

TLR agonists can promote TLR recognition of pattern-associated molecular patterns to initiate innate immunity [30, 31]. Innate immune cells are then recruited to present the antigen, eventually priming and boosting adaptive immunity [32, 33]. These complicated steps have emphasized the critical roles of macrophages, DCs and T cells [34]. Consequently, the regulation of immune cells by Nano\textsuperscript{PCPT+PIMDQ} was further studied in vivo. After four administrations, the mice were sacrificed in each group, and the lymphocytes of spleens and TDLNs were harvested to evaluate the immune response. It has been reported that most of the T cells in tumors are derived from TDLNs, followed by their expansion in tumor tissue [35]. Thus, the elevated percentage of CD8\(^+\) T cells in TDLNs revealed that Nano\textsuperscript{PCPT+PIMDQ} might increase T-cell activity at the tumor site. In addition, CD8\(^+\) T cells showed upregulated protein expression of granulocytin B (GrB) and tumor necrosis factor factor α (TNF-α) upon treatment with Nano\textsuperscript{PCPT+PIMDQ}. Nano\textsuperscript{PCPT+PIMDQ} also elicited a higher percentage of interferon-γ (IFN-γ)-producing CD4\(^+\) T cells. These results indicated that Nano\textsuperscript{PCPT+PIMDQ} enhanced antigen presentation and promoted T-cell effector function (Fig. 6a–f). In mice receiving Nano\textsuperscript{PCPT+PIMDQ}, the total percentage of macrophages (F4/80\(^+\)) was upregulated (Fig. 6g). In particular, although the amount of M2 macrophages (CD206\(^+\)) did not change obviously, the proportion of M1 macrophages (iNOS\(^+\)) and the M1/M2 ratio were increased, indicating that macrophages had transformed from M2 to M1-like macrophages. In addition, MHC-I and MHC-II were expressed to a greater extent on the surface of DCs treated with Nano\textsuperscript{PCPT+PIMDQ} than on the surface of DCs treated with control agents (Fig. 6h). Moreover, the number of Treg cells (CD4\(^+\)Foxp3\(^+\) T cells) decreased in the mice receiving the CPT-containing treatment, demonstrating the Treg inhabitation (Fig. 6i).

The spleen, the largest immune organ, plays a critical role in systemic immunity [36–38], and the lymphocytes isolated from it were used here to evaluate the immune response of Nano\textsuperscript{PCPT+PIMDQ}. The results demonstrated that Nano\textsuperscript{PCPT+PIMDQ} effectively boosted the beneficial effects on immune response.

(See figure on next page.)

**Fig. 5** Nano\textsuperscript{PCPT+PIMDQ} improved antitumor efficiency in vivo. a Antitumor experimental design timeline of CT26-bearing BALB/c mice. b Proximal tumor growth curves of mice following treatment with PBS, CPT, Nano\textsuperscript{PCPT} and Nano\textsuperscript{PCPT+PIMDQ} (n=6). c Weight and d photograph of proximal tumors harvested from the mice on Day 21 (n=6). e Kaplan–Meier curves of the mice following different treatments. f Body weight change profile of mice during the treatment period (n=6). g Distal tumor growth profiles of the mice following different treatments (n=6). h H&E, Ki67, and TUNEL staining images of tumor slides collected from CT26-bearing BALB/c mice after treatment (H&E 400 × , Ki67 50 × , and TUNEL 40 × ). Data are shown as the mean ±SD. *p<0.05, **p<0.01, ***p<0.001
Fig. 5 (See legend on previous page.)
immune function of the spleen. Increased CD8+ T and CD4+ T cell numbers, along with elevated GrB and IFN-γ respectively expression in CD8+ T and CD4+ T cells, suggested a cytolytic role (Fig. 7a–e). CD103+ DCs are a core subgroup in antigen-presenting cells to promote the production of tumor antigen-specific CD8+ T cells, and Fig. 7f showed that administration of NanoPCPT+PIMDQ generated more CD103+ DCs than other treatments. The costimulatory molecule CD86 and the antigen-presenting molecules MHC-I and MHC-II on the surface of DCs verified their activation in the spleen. The number of Treg cells (CD4+Foxp3+ T cells) were also decreased in mice receiving CPT-containing treatment (Fig. 7g). Fortunately, we also observed the formation of effector memory T cells (Tem, CD44+CD62L− T cells) gated on CD4+ T and CD8+ T cells in spleens upon the NanoPCPT+PIMDQ group (Fig. 7h). These results demonstrated that NanoPCPT+PIMDQ effectively primed the immune response after administration and subsequently promoted antitumor effects.
To investigate the immunocomponent within tumors, we performed a large tumor model (> 200 mm³) and pretreated with different formulations via intratumoral injection. Compared with other groups, NanoPCPT+PIMDQ treatment elevated the infiltration of CD8⁺ T cells within tumors. The expression or secretion of GrB, TNF-α, IFN-γ on CD8⁺ T cells were upregulated, demonstrating their activation (Fig. 8a, b). Meanwhile, CD4⁺ T cells proportion were also elevated after treatment with NanoPCPT+PIMDQ and the expression or secretion of ICOS, IFN-γ and TNF-α were upregulated (Fig. 8c). Treg cells are an essential subset of immunosuppressive cells. Foxp3, as the master gene of Treg cells, is required for immunosuppressive function. The accumulation of Foxp3⁺ Treg cells is linked to disease progression and immunosuppression and may alter CD8⁺ T-cell activity [39]. Hence, cancer immunotherapy may be improved by specifically
inhibiting Treg cells [40]. As shown in Fig. 8d, the number of Treg cells (CD4<sup>+</sup>Foxp3<sup>+</sup> T cells) decreased in tumors in mice receiving the CPT-containing treatment, which was in line with earlier research [9]. Subsequently, CD11c antibody was used to label DC to investigate their activation status. Nano<sub>PCPT+PIMDQ</sub> treatment increased the expression of CD40 and CD80 in comparison with other groups (Fig. 8e). Additionally, Nano<sub>PCPT+PIMDQ</sub> induced the re-polarization of TAMs based on the downregulation of M2 TAMs and upregulation of M1 TAMs (Fig. 8f). These results indicated that Nano<sub>PCPT+PIMDQ</sub> hold promise for triggering robust antitumor immune response within tumors.

**Conclusions**

In summary, we developed a sequential pH/GSH-responsive triblock polymeric nanomicelle system that codelivers the chemotherapeutic drug CPT and the TLR7/8 agonist IMDQ, inducing amplified chemioimmunotherapy of colorectal cancer. First, Nano<sub>PCPT+PIMDQ</sub>
responding to the tumor acidic microenvironment achieved charge reversal and dispersed into smaller micelles, consequently increasing intracellular uptake and improving the penetration of NanoPCPT inside tumor tissue. Subsequently, GSH-triggered CPT was released from PCPT in tumor cells. In addition to the chemotherapeutic killing effect, CPT lowered the number of Treg cells (CD4<sup>+</sup>Foxp3<sup>+</sup>) in TDLNs and spleens, allowing the infiltration of cytotoxic T cells into tumors. The exposed PIMDQ remodeled M2 macrophages into M1 macrophages and activated DCs to prime T cells, which further stimulated tumor-specific immune responses. In the CT26 colon tumor model, we showed that NanoPCPT+PIMDQ markedly inhibited the growth of primary and distal tumors. As a consequence, our strategy provides a promising nanoplatform for the codelivery of specific drugs to orchestrate chemoimmunotherapy.

**Materials and methods**

**Materials**

4-Cyano-4-(dodecysulfanylthiocarbonyl) sulfanyl penta- noic acid (DCT), N,N’-dicyclohexylcarbodiimide (DCC), acetonitrile oxime, monomethoxy PEG (Mw = 5000 Da), and 2,2’-azobisisobutyronitrile (AIBN) were purchased from Sigma–Aldrich. 2-Hydroxyethyl disulfide was purchased from Macklin, and 4-(N,N-dimethylamino) pyridine (DMAP) was purchased from Heowns. Triphosgene, methacryl chloride, N-ethylthanolamine, propyl bromide, and camptothecin were obtained from Energy Chemical. C6(6)-TAMRA cadaverine (Rho) was purchased from Haoran Biological Technology Co., Ltd. Cyanine 5.5 amine was purchased from Lumiprobe. 4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Beyotime Biotechnology Co., Ltd. Cell counting kit-8 (CCK-8) was purchased from Beijing Solarbio Technology Co., Ltd. An Annexin V-FITC/PI apoptosis detection kit was purchased from Mei Lun Biological Technology Co., Ltd. (Dalian, China). 1-(4-(Aminomethyl)benzyl)-2-butyl-1H-imidazo[4,5-c] quinoline-4-amine (IMDQ) was provided by Nanjing Aikon Chemical Ltd. Anti-CD11c, anti-CD86, anti-CD80, anti-CD40, anti-GrB, anti-TNF-α, anti-CD3e, anti-IFN-γ, anti-MHC-I, anti-MHC-II, anti-CD103, anti-F4/80, anti-CD206, anti-iNOS, anti-CD4, anti-CD8, anti-Foxp3, anti-CD44, anti-CD62L were purchased from Biolegend (American).

**Cell lines**

A murine colorectal cell line (CT26) and macrophages were obtained from the School of Pharmacy, Shandong University. CT26 cells were cultured with RPMI-1640 complete growth medium supplemented with 10% fetal bovine serum and 2% penicillin/streptomycin and incubated at 37 °C with 5% CO₂ saturation. Macrophages were cultured with DMEM complete growth medium supplemented with 10% fetal bovine serum and incubated at 37 °C with 5% CO₂ saturation. Bone marrow-derived DCs (BMDCs) were obtained from the bone marrow cells of five-week-old male C57BL/6 mice and cultured in 1640 containing recombinant mouse granulocyte–macrophage colony stimulating factor (GM-CSF) and IL-4.

**Animals**

Healthy male BALB/c mice (3–5 weeks old) were purchased from Beijing Huafukang Biotechnology Co., Ltd. The Medical Animal Test Center at Shandong University provided male C57BL/6 mice (5–7 weeks old).

**Synthesis of N-ethyl-N-propylethanolamine (EPEMA)**

EPEMA was synthesized according to the reported literature with some modifications [41]. After dissolving N-ethyl-N-propylethanolamine (27.42 g, 0.3 mol), sodium carbonate (47.7 g, 0.45 mol), and propyl bromide (44.28 g, 0.36 mol) in ethanol (100 mL), the mixture was heated to 80 °C for 24 h. The mixture was filtered, and the obtained filtrate was concentrated, extracted with DCM, and evaporated under reduced pressure to obtain the product (Additional file 1: Fig. S2). HNMR (400 MHz, CDCl₃, δ): 3.53 (t, J = 5.5 Hz, 2H), 2.56 (p, J = 7.1, 6.2 Hz, 4H), 2.42 (dd, J = 8.6, 6.5 Hz, 2H), 1.46 (p, J = 7.4 Hz, 2H), 1.02 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H).

**Synthesis of N-ethyl-N-propyl-aminoethanol methacrylate (EPEMA)**

EPEMA was synthesized according to the reported literature with some modifications [41]. After dissolving N-ethyl-N-propylethanolamine (3 g, 22.9 mmol) and triethylamine (2.317 g, 22.9 mmol) in acetonitrile (20 mL), the mixture was cooled to 0 °C. Methacryl chloride (2.394 g, 22.9 mmol) was added dropwise. The mixture was stirred at 0 °C for 2 h and at room temperature for another 12 h. The mixture was filtered, and the obtained filtrate was extracted with DCM and evaporated under reduced pressure to give the monomer EPEMA (Additional file 1: Fig. S3). HNMR (400 MHz, CDCl₃, δ): 6.09 (t, J = 1.4 Hz, 1H), 5.60–5.51 (m, 1H), 4.20 (t, J = 5.5 Hz, 2H), 2.75 (t, J = 6.3 Hz, 2H), 2.58 (q, J = 7.1 Hz, 2H), 2.53–2.39 (m, 2H), 1.94 (t, J = 1.3 Hz, 3H), 1.51–1.40 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H).
was stirred at room temperature for 1 h. Next, the layers were separated, and the aqueous phase was extracted with DCM (3 × 50 mL). After being concentrated under reduced pressure, the organic phase was washed with saturated NaHCO₃ aqueous solution (3 × 50 mL) and then water (50 mL). The organic phase was dried over Na₂SO₄, was filtered, and then, the obtained filtrate was evaporated in vacuo to afford AA (Additional file 1: Fig. S4), which was used directly without purification. ¹H NMR (400 MHz, CDCl₃, δ): δ 8.69 (s, 1H), 8.14 (t, J = 9.2 Hz, 2H), 7.86 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.72 (t, J = 7.4 Hz, 1H), 6.01–5.93 (m, 1H), 5.64 (q, J = 1.7 Hz, 1H), 5.52 (d, J = 2.0 Hz, 2H), 5.30 (d, J = 3.2 Hz, 2H), 4.40–4.22 (m, 4H), 3.10–2.90 (m, 4H), 2.17 (dq, J = 10.3, 7.1 Hz, 2H), 1.81 (d, J = 1.3 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H) (Additional file 1: Fig. S5).

Synthesis of OH-2S-CPT
To synthesize OH-2S-CPT, we first synthesized 2-[(2-hydroxyethyl)dithio]ethyl-2-methyl-2-propenoate as reported in the literature [43]. Briefly, 2-hydroxyethyl disulfide (1290 mg, 8.36 mmol) and TEA (845.9 mg, 8.36 mmol) were dissolved in tetrahydrofuran (THF) (20 mL) and cooled to 0 °C in an ice bath. Methacryl chloride (873.8 mg, 8.36 mmol) was added slowly to the mixture at 0 °C. The mixture was stirred at 0 °C for 2 h and at room temperature overnight. The mixture was filtered, and the obtained filtrate was extracted with EtOAc and concentrated under reduced pressure to afford AA (Additional file 1: Fig. S4), which was used to determine the monomer conversion (Additional file 1: Fig. S7).

Synthesis of the triblock polymer prodrug PEG-PEPEMA-PCPT (PCPT)
The polymerization of PEG-PEPEMA-PCPT also used RAFT polymerization. PEG-PEPEMA (356 mg, 0.024 mmol), OH-2S-CPT (432.8 mg, 0.725 mmol), and AIBN (1.2 mg, 0.007 mmol) were dissolved in dioxane and dimethyl sulfoxide (DMSO) (volume ratio = 1:1) and placed into Schlenk tubes. After four freeze–pump–thaw cycles, the mixture was heated to 80 °C to initiate polymerization and stirred for 48 h. The solution was cooled, and the polymer prodrug was purified by triple precipitation in cold ether to afford the polymer prodrug (Additional file 1: Fig. S8). The drug grafting rate was determined by UV–vis analysis (Additional file 1: Fig. S11).

Synthesis of PEG-PEPEMA-PAA
The polymerization of PEG-PEPEMA-PAA also used RAFT polymerization. PEG-PEPEMA (642 mg, 2.51 mmol), AIBN (1.2 mg, 0.013 mmol), and TEA (845.9 mg, 8.36 mmol) were dissolved in dioxane and placed into a Schlenk tube. After four freeze–pump–thaw cycles, the mixture was heated to 75 °C to initiate polymerization and stirred for 48 h. The solution was cooled and purified by dialysis against water. PEG-PEPEMA-PAA was obtained by lyophilization. ¹H NMR spectroscopy was used to determine the monomer conversion (Additional file 1: Fig. S9).

Synthesis of diblock polymer PEG-PEPEMA
PEG-PEPEMA was synthesized by the reversible addition-fragmentation chain transfer (RAFT) polymerization technique. Briefly, PEG-DCT (270.24 mg, 0.050 mmol), EPEMA (500 mg, 2.51 mmol), and AIBN (2.47 mg, 0.015 mmol) were dissolved in dioxane and placed into Schlenk tubes. After four freeze–pump–thaw cycles, the mixture was heated to 70 °C to initiate polymerization and stirred for 48 h. The solution was cooled and purified by dialysis against water. PEG-PEPEMA was obtained by lyophilization. The product was then dried under vacuum overnight to obtain a pale yellow powder (Additional file 1: Fig. S6).

Synthesis of PEG-PEPEMA-PCPT (PCPT)
The polymerization of PEG-PEPEMA-PCPT also used RAFT polymerization. PEG-PEPEMA (356 mg, 0.024 mmol), OH-2S-CPT (432.8 mg, 0.725 mmol), and AIBN (1.2 mg, 0.007 mmol) were dissolved in dioxane and dimethyl sulfoxide (DMSO) (volume ratio = 1:1) and placed into Schlenk tubes. After four freeze–pump–thaw cycles, the mixture was heated to 80 °C to initiate polymerization and stirred for 48 h. The solution was cooled, and the polymer prodrug was purified by triple precipitation in cold ether to afford the polymer prodrug (Additional file 1: Fig. S8). The drug grafting rate was determined by UV–vis analysis (Additional file 1: Fig. S11).

Synthesis of the triblock polymer prodrug PEG-PEPEMA-PCPT (PCPT)
The polymerization of PEG-PEPEMA-PCPT also used RAFT polymerization. PEG-PEPEMA (642 mg, 2.51 mmol), AA (166.4 mg, 1.309 mmol), and AIBN (2.15 mg, 0.013 mmol) were dissolved in dioxane and placed into a Schlenk tube. After four freeze–pump–thaw cycles, the mixture was heated to 75 °C to initiate polymerization and stirred for 48 h. The solution was cooled and purified by dialysis against water. PEG-PEPEMA-PAA was obtained by lyophilization (Additional file 1: Fig. S7).

Synthesis of PEG-PEPEMA-PAA
The polymerization of PEG-PEPEMA-PAA also used RAFT polymerization. PEG-PEPEMA (642 mg, 2.51 mmol), AA (166.4 mg, 1.309 mmol), and AIBN (2.15 mg, 0.013 mmol) were dissolved in dioxane and placed into Schlenk tube. After four freeze–pump–thaw cycles, the mixture was heated to 75 °C to initiate polymerization and stirred for 48 h. The solution was cooled and purified by dialysis against water. PEG-PEPEMA-PAA was obtained by lyophilization (Additional file 1: Fig. S7).

Synthesis of PEG-PEPEMA-PAA-PIMDQ (PIMDQ)
To connect IMDQ, we employed the amino group on IMDQ and the PAA on the polymer to conduct a substitution process. PEG-PEPEMA-PAA (20 mg, 0.00115 mmol), IMDQ (5.4 mg, 0.0125 mmol), and TEA (3.79 mg, 0.0374 mmol) were dissolved in dioxane and placed into a Schlenk tube. After four freeze–pump–thaw cycles, the mixture was heated to 75 °C to initiate polymerization and stirred for 48 h. The solution was cooled and purified by dialysis against water. PEG-PEPEMA-PAA was obtained by lyophilization. The product was then dried under vacuum overnight to obtain a pale yellow powder (Additional file 1: Fig. S6).
powder was obtained by lyophilization. The IMDQ grafting rate was determined by UV–vis analysis (Additional file 1: Fig. S12).

**Synthesis of PEG-PEPEMA-PAA<sup>Rho</sup>**
To fluorescently label the polymer, we employed the amino group on Rho and the PAA on the polymer to conduct a substitution process. In short, PEG-PEPEMA-PAA (0.0034 mmol), Rho (0.67 μmol), and TEA (0.036 mmol) were dissolved in dioxane and stirred at 50 °C for 48 h under N₂ protection. The solution was cooled and dialyzed against water for 24 h to remove free Rho. A pink powder was obtained by lyophilization.

**Synthesis of PEG-PEPEMA-PAA<sup>Cy5.5</sup>**
To fluorescently label the polymer, we employed the amino group on Cy5.5 and the PAA on the polymer to conduct a substitution process. In short, PEG-PEPEMA-PAA (0.003 mmol), NH₂-Cy5.5 (0.7 μmol), and TEA (0.038 mmol) were dissolved in dioxane and stirred at 50 °C for 48 h under N₂ protection. The solution was cooled and dialyzed against water for 24 h to remove free Cy5.5. A green powder was obtained by lyophilization.

**Self-assembly of PEG-PEPEMA-PCPT and PEG-PEPEMA-PIMDQ triblock polymer mixture nanomicelles (Nano<sub>PCPT</sub>+PIMDQ)**
After dissolving PEG-PEPEMA-PCPT (11.25 mg) and PEG-PEPEMA-PIMDQ (1.7 mg) in dimethyl sulfoxide (0.3 mL), the above solution was dropped into Milli-Q water (3 mL) under ultrasound. The mixture was sonicated for 30 min to create nanomicelles. To remove DMSO, the solution was dialyzed against deionized water overnight. Finally, the stock solution was diluted to 3 mg·mL⁻¹ and stored in the dark at 4 °C for further experiments.

**Preparation of TAMRA-labeled nanomicelles (Nano<sub>Rho</sub>)**
Similarly, PEG-PEPEMA-PTAMRA was dissolved in DMSO and then added dropwise into Milli-Q water under continuous sonication. After sonication for 30 min, the solution was dialyzed against deionized water for 24 h to remove DMSO. Finally, the stock solution (10 mg·mL⁻¹) was stored in the dark at 4 °C for further testing.

**Preparation of Cy5.5-labeled nanomicelles (Nano<sub>Cy5.5</sub>)**
The Cy5.5-labeled polymer was dissolved in DMSO and then added dropwise into Milli-Q water under constant sonication. After 30 min, the solution was dialyzed against deionized water for 24 h to remove DMSO. Finally, the stock solution (10 mg·mL⁻¹) was stored in the dark at 4 °C for further experiments.

**Characterization of Nano<sub>PCPT</sub>+PIMDQ**
We diluted the micelle stock solution with various pH buffers to investigate the pH effect on micelles. After overnight incubation at 37 °C, dynamic light scattering (DLS) was used to determine the count rate and zeta potential, and TEM was used to examine the micelle morphology.

**Drug grafting rate**
According to Lambert–Beer law, under the same experimental conditions, the absorbance (A) is proportional to the concentration (C). The certain concentrations of CPT and IMDQ were used as the controls (C<sub>control</sub>) and absorbance were determined by UV–visible (UV–vis) spectrophotometry at 365 nm and 326 nm, respectively (A<sub>sample</sub>). The drug-grafting content (DGC) were calculated as follows formula:

\[
W_{\text{CPT(IMDQ)}} = V \times C_{\text{sample}} = V \times \left( C_{\text{control}} \times A_{\text{sample}} \right) / A_{\text{control}}; \\
\text{DGC} (%) = \left( W_{\text{CPT(IMDQ)}} / W_{\text{PEG–PEPEMA–PCPT(PEG–PEPEMA–PIMDQ)}} \right) \times 100%.
\]
The DGC results of CPT and IMDQ were $34.09 \pm 0.46\%$ and $13.62 \pm 0.19\%$ respectively (Additional file 1: Figs. S11-S12).

**In vitro drug release of CPT triggered by the reducing agent dithiothreitol (DTT)**

In a shaking incubator at $37^\circ C$, a NanoPCPT dispersion in pH 7.4 phosphate-buffered saline (PBS) was placed into a dialysis bag (3500 Da MWCO), which was then dialyzed against the buffered medium in the absence or presence of DTT (10 mM). An aliquot of the external medium was withdrawn and replaced with an equal volume of new buffer solution at various periods. HPLC was used to measure CPT concentrations in the media at different time intervals using a 365 nm absorption wavelength.

**Cultivation of tumor spheroids**

As reported in the literature, the hanging drop technique was used to prepare tumor spheroids [45]. CT26 cells were resuspended at $400,000\text{-}mL^{-1}$ in 0.25% methylcellulose, and 20 μL of suspension was transferred dropwise to the lid of the 48-well plate, with PBS (200 μL\text{-}well$^{-1}$) supplied to each well to maintain the humidity of the hanging drop. After incubating at $37^\circ C$ with 5% CO2 for 4 days, the tumor spheroids were transferred to a 48-well plate containing fresh culture medium for further study.

**In vitro evaluation of tumor penetration of nanomicelles**

The obtained tumor spheroids were transferred to 48-well plates with fresh media (pH 7.4 or 6.5) containing NanoCy5.5 (Cy5.5 = 2 μg\text{-}mL$^{-1}$). After incubation for 6 h, the tumor spheroids were washed twice with ice-cold PBS and fixed with 1% paraformaldehyde. Subsequently, z-stack images were obtained with a confocal laser scanning microscope.

**In vitro effect of pH on intracellular trafficking of nanomicelles**

CT26 cells were plated in a 48-well plate with 100,000 cells per well and incubated for 12 h at 37 °C with 5% CO2. The culture media were removed, and the cells were treated with fresh media (pH 7.4 or 6.5) containing NanoCy5.5. After 12 h, the supernatant was removed, the cells were separated, washed with cold PBS, and resuspended in PBS, and the sample was measured using flow cytometry.

**In vitro Cytotoxicity Assay by CCK-8**

CT26 cells were plated at 5000 cells per well in a 96-well plate and incubated for 12 h. Afterward, the supernatant was removed by pipette aspiration and replaced with a series of media containing free CPT, NanoPCPT, and Nano$^{\text{blank polymer}}$ at a series of concentrations, followed by incubation for another 24 h. Subsequently, the drug-containing medium was removed by pipette aspiration, replaced with fresh medium, and then incubated for 48 h. Next, CCK-8 (10 μL) was added to each well and incubated for 40 min, and the absorption was measured at 465 nm. The other operations were the same as those for CT26 cells, with the exception of incubating macrophages with 3 μM CPT and NanoPCPT containing the same quantity of CPT.

**In vitro BMDC uptake**

Murine BMDCs were obtained and cultured from C57BL/6 mice. BMDCs were cultured with medium containing Nano^Rho for 2, 6, 12, 24 h. Afterward, the cells were collected, washed with cold PBS twice, and resuspended in PBS, and the sample was measured using flow cytometry.

**In vitro BMDC activation**

To explore the effect of polymer-modified IMDQ on the activation of BMDCs, we incubated BMDCs with different concentrations of free IMDQ and Nano^PMDQ in a 48-well plate for 48 h. Cells were then collected and stained with anti-CD11c, anti-CD86, anti-CD80, anti-MHC-II-BV786, and anti-CD40 to determine the specific DC maturation marker expression by flow cytometry (FACS Celesta) and analyzed using FlowJo software.

**In vitro macrophage repolarization**

RAW264.7 macrophage cells were seeded in a 12-well plate at a density of 500,000 cells/well overnight. After adding IL-4 for 24 h to simulate polarization into M2 macrophages, various concentrations of IMDQ and Nano^PMDQ were added for incubation for another 24 h. Cells were then collected and stained with anti-F4/80, anti-CD200R, and anti-iNOS to determine the expression of specific macrophage repolarization markers by flow cytometry (FACS Celesta) and analyzed using FlowJo software.

**IVIS imaging and biodistribution in vivo**

CT26-bearing mice were obtained by inoculating 800,000 CT26 cells on the backs of male BALB/c mice. When tumor sizes grew to 100–200 mm$^3$, mice were used for biodistribution studies. After Nano^Cy5.5 intratumoral injection, real-time fluorescence images of the anesthetized mice were captured by an in vivo imaging system at different time points (1, 24, 48, 96, and 120 h) to investigate the time-dependent retention of Nano^Cy5.5 in tumors. The mice were sacrificed, and their major organs were excised for in vitro imaging. The excised livers and
Subcutaneous Tumor Model Evaluation
CT26 cells (750,000) in PBS were injected subcutaneously into the right back of BALB/c mice (5–7 weeks old), followed three days later by subcutaneous injection of the same density of CT26 cells in the left back. When the proximal tumors grew to 50–60 mm³, the mice bearing different groups of medicine: 1. PBS; 2. CPT; 3. NanoPCPT; 4. NanoPIMDQ; and 5. NanoPCPT+PIMDQ. CPT was administered at a dose of 10 mg·kg⁻¹, while IMDQ was given at a dose of 0.5 mg·kg⁻¹ body weight. The mice received a total of four treatments, and they were given drugs every three days. The body weight and tumor volumes were recorded regularly, and the tumor volumes (V) were calculated from the following equation: $V = \frac{LW^2}{2}$ (L = length of tumor longest axis; W = length of the axis perpendicular to the longest axis of the tumor). The survival of the mice was closely monitored throughout the experiment.

In vivo antitumor immune response post-administration
To assess whether our mixed nanomicelles could elicit an improved immune response, mice from each group were dissected after four intratumoral injections. Subsequently, tumor-draining lymph nodes and spleen were removed from the mice to prepare a single immune cell suspension. Anti-CD3, anti-CD4, anti-CD8, anti-GrB, anti-TNF-α, and anti-IFN-γ were labeled to measure cytotoxic T-cell activation in TDLNs, and anti-CD4, anti-CD8, anti-CD3, and anti-GrB, anti-IFN-γ were labeled to measure cytotoxic T-cell activation in the spleen. Anti-CD11c, anti-MHC-I, and anti-MHC-II were labeled to assess DC cell maturation in TDLNs, and anti-CD86, anti-CD103, anti-MHC-I, and anti-MHC-II were labeled to assess DC cell maturation in spleens. Anti-F4/80, anti-CD206, and anti-iNOS were labeled to evaluate macrophage repolarization. These cells were performed via flow cytometry (FACS Celesta) and analyzed via FlowJo software.

Antitumor immune response in vivo at the end of treatment
We prepared single-cell suspensions from the tumors, tumor-draining lymph nodes and spleen for immunological analysis and evaluation. Single-cell suspensions of tumors, lymph nodes and spleens were stained with anti-CD4, anti-Foxp3 for the analysis of Treg cells. A single-cell suspension of spleens was stained with anti-CD4 and anti-CD62L to analyze immune memory and the effector memory T cells were based on the CD44⁺ CD62L⁻ phenotype.

Anti-tumor immune response within tumors
To investigate the immune response within tumors, we performed a large tumor model (> 200 mm³) and pre-treated with different formulations via intratumoral injection. After treatment, single-cell suspensions collected from tumors were labeled with anti-CD3e, anti-CD4, anti-CD8 to evaluate T cell infiltration; anti-GrB, anti-TNF-α, anti-IFN-γ, and anti-ICOS to evaluate the activation of T cells; anti-CD4 and anti-Foxp3 to evaluate Treg cells; anti-CD11c, anti-CD40, and anti-CD80 to evaluate DCs maturation; anti-F4/80, anti-CD206, and anti-iNOS to evaluate macrophage repolarization. These cells were performed via flow cytometry (FACS Celesta) and analyzed via FlowJo software.

Immunohistochemical analysis
Main organs and tumors were taken and fixed with 4% formaldehyde before being stained with hematoxylin and eosin (H&E) for an in vivo safety investigation, and tumors were further stained with Ki67 and TUNEL for further research.

Statistical analysis
Student’s t test was used for statistical analysis, and the results are expressed as the means ± SD. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001. (GraphPad Software, CA, USA).

Abbreviations
RAFT: Reversible Addition-Fragmentation Chain Transfer; AA: Acryloyl acetone oxime; EPEMA: 2-[(N-ethyl-N-propyl amino) ethyl] methacrylate; IMDQ: 1-(4-(Aminomethyl) benzyl)-2-butyl-1H-imidazo[4,5-c] quinoline-4-amine; CPT: Camptothecin; PCPT: PEG-PEPEMA-PCPT; PIMDQ: PEG-PEPEMA-PIMDQ; AA: Acryloyl acetone oxime; EPEMA: 2-[(N-ethyl-N-propyl amino) ethyl] methacrylate; Orh-2S-CPT: Reduction-responsive CPT monomer; PEG: Monomethoxy poly (ethylene glycol); DCT: 4-Cyano-4-(dodecylsulfanylthiocarbonyl) sulfanyl pentanoic acid; ABIN: 2′,2′-(Azobisis(2-methylpropionitrile)); DCC: N,N′-Dicyclohexylcarbodiimide; DMAP: 4-((N,N-dimethylamino) pyridine; MQ: Imiquimod; TEA: Triethylamine; Rho: 5(6)-TAMRA cadaverine; cy5.5: Cyanine 5.5 amine; DCM: Dichloromethane; DMSO: Dimethyl sulfoxide; DMSO-d6: Dimethyl sulfoxide-d6; CDCl₃: Trichloromethane-d; EtOAc: Ethyl acetate; DP: Degree of polymerization; GSH: Glutathione; DTT: Dithiothreitol; DLS: Dynamic light scattering; UV–vis: Ultraviolet and visible spectrophotometry; CLSM: Confocal laser scanning microscopy; CCK-8: Cell counting Kit-8; MICS: 3D multicellular spheroids; TAMs: Tumor-associated macrophages; BMDCs: Bone marrow-derived dendritic cells; TDLNs: Tumor draining lymph nodes; TEM: Transmission electron microscope; DCs: Dendritic cells; DMEM: Dulbecco’s modified eagle medium; DMSO: Dimethyl sulfoxide; H&E: Hematoxylin and eosin; DAPI: 4′,6-Diamidino-2-phenylindole.
The online version contains supplementary material available at https://doi.org/10.1186/s12951-022-01577-5.

Supplementary Information

Additional file 1. Sequential acid/reduction response of triblock copolymeric nanomicelles to release camptothecin and toll-like receptor 7/8 agonist for orchestrated chemoimmunotherapy. Figure S1. The synthetic route of EPEMA, AA, OH-25-CPT. Figure S2. 1H-NMR spectrum of 2-(N-Ethyl-N-propyl) ethanol amine. Figure S3. 1H-NMR spectrum of EPEMA. Figure S4. 1H-NMR spectrum of AA. Figure S5. 1H-NMR spectrum of OH-25-CPT. Figure S6. 1H-NMR spectrum of PEG-DCT. Figure S7. 1H-NMR spectrum of PEG-PEPEMA. Figure S8. 1H-NMR spectrum of PEG-PEPEMA-PCPT. Figure S9. 1H-NMR spectrum of PEG-PEPEMA-PCPT. Figure S10. 1H-NMR spectrum of PEG-PEPEMA-PIMDQ. Figure S11. UV-vis spectrum of PEG-PEPEMA-PIMDQ. Figure S12. UV-vis spectrum of PEG-PEPEMA-PAA. Figure S13. DTT-triggered CPT release from Nano PCPT in vitro, at the release medium with different pH values. Figure S14. CT26 cytotoxicity of PEG-PEPEMA-PAA polymer detected by CCK-8. Figure S15. In vitro uptake of nanomicelles by BMDCs at different times (n=3). Figure S16. The flow cytometric images of in vitro BMDCs maturation. Figure S17. H&E (200x, bar 100 μm) staining of major organs slides after the final treatment in different preparation groups. Figure S18. Representative flow cytometric analysis images of CD11c+ MHC-I+ in spleens.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (82003680, ZR2020QH350, ZR2021QH024), and Chinese “post-doctoral international exchange program”. We thank Translational Medicine Core Facility of Shandong University for consultation and instrument availability that supported this work.

Author contributions

YG and YH. Methodology, Software, Formal analysis, Investigation, Writing—Original Draft. HL. Validation, Formal analysis, Project administration. HZ. Software, Methodology. YL. Validation, Methodology. YL. Validation, Investigation. XL. Visualization, Investigation. HC. Investigation. JZ. Visualization. SZ. Methodology. LH. Resources, Data Curation. GS. Resources, Data Curation. ZZ. Conceptualization, Validation, Investigation, Methodology, Writing—Review and Editing, Supervision, Project administration, Funding acquisition. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82003680, ZR2020QH350, ZR2021QH024), and Chinese “post-doctoral international exchange program”. We thank Translational Medicine Core Facility of Shandong University for consultation and instrument availability that supported this work.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

All animal experiments were carried out in accordance with the Health Guide for the Care and Use of Laboratory Animals of the National Institutes and approved by the Shandong University Animal Experiment Ethics Review (Approval No. 19032).

Consent for publication

All authors agree to be published.

Competing interests

The authors have declared that no competing interest exists.

Author details

1. NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeolo College of Medicine, Shandong University, Jinan, Shandong 250012, People’s Republic of China.
2. Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Cheeolo College of Medicine, Shandong University, Jinan, Shandong 250012, People’s Republic of China.
3. Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeolo College of Medicine, Shandong University, Jinan, Shandong 250012, People’s Republic of China.

Received: 26 February 2022 Accepted: 26 July 2022 Published online: 11 August 2022

References

1. Chen L, Qin H, Zhao R, Zhao X, Lin L, Chen Y, Lin Y, Li Y, Qin Y, Li Y, et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci Transl Med. 2021;13:eabc2816.
2. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumors with combination immunotherapies. Nat Rev Drug Discovery. 2019;18:197–218.
3. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrielovitch D, Oststrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50.
4. Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482–92.
5. Dienstmann R, Vermeulen L, Guinneny J, Kopetz S, Teigas S, Tabenero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.
6. Schmidt M, Oswald D, Vaz B, Wittig B, Kapp K. Modulation of T cell and macrophage tumor infiltration by the TLR9 agonist lenofilimod in a murine model of colorectal cancer. J Clin Oncol. 2018;36:687–687.
7. Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6:605–18.
8. Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered immune niches for reprogramming the immune-suppressive tumor microenvironment and enhancing cancer immunotherapy. Adv Mater. 2019;31:1803322.
9. Hibuino S, Chikusa S, Konodo T, Toh M, Nakatsukasa H, Omata-Misui S, Yoshimura A. Inhibition of Nr4a receptors enhances antitumor immunity by breaking treg-mediated immune tolerance. Cancer Res. 2018;78:3027–40.
10. Wang L, He Y, He T, Liu G, Lin C, Li K, Lu L, Cai K. Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine-based nanocarriers. Biomaterials. 2020;255:120208.
11. Bolli E, Schreger M, Amouk SM, Pombo Antunes AR, Strahlburger D, Uirschbach M, Stickdorn M, De Vlamink C, Movahedi K, Räder HJ, et al. Targeted repolarization of tumor-associated macrophages via imidazquinolined-linked nanobodies. Adv Sci. 2021;8:2004574.
12. Li Z, Yang Y, Wei H, Shan X, Wang X, Ou M, Liu Q, Gao N, Chen H, Mei L, et al. Charge-reversal biodegradable MSNs for tumor synergetic chemo/photothermal and visualized therapy. J Control Release. 2021;338:719–30.
13. Wang H-X, Zuo Z-Q, Du J-Z, Wang Y-C, Sun R, Cao Z-T, Ye X-D, Wang J-L, Leong KW, Wang J. Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines. Nano Today. 2016;11:133–44.
14. Wang C-S, Chang C-H, Tseng T-Y, Lin AM-H, Yo Y-L. Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression. Nanoscale Horizons. 2021;6:729–743.
15. Ao M, Yu F, Li Y, Zhong M, Tang Y, Yang H, Wu X, Zhuang H, Wang H, Sun X, et al. Carrier-free nanoparticles of camptothecin produrg for chemo-pho-tothermal therapy: the making, in vitro and in vivo testing. J Nanobiotechnology. 2021;19:350.

16. Feng L, Yang L, Li L, Xiao J, Bie N, Xu C, Zhou J, Liu H, Gan L, Wu Y. Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy. Nano Res. 2022;15:593–602.

17. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991–1003.

18. Wang S, Yu G, Wang Z, Jacobson O, Tian R, Lin L-S, Zhang F, Wang J, Chen X. Hierarchical tumor microenvironment-responsive nanomedicine for programmed delivery of chemotherapeutics. Adv Mater. 2018;30:1803926.

19. Wei P, Sun M, Yang B, Xiao J, Du J. Ultrasound-responsive polymersomes capable of endosomal escape for efficient cancer therapy. J Control Release. 2020;322:81–94.

20. Ding Y, Dai Y, Wu M, Li L. Glutathione-mediated nanomedicines for cancer diagnosis and therapy. Chem Eng J. 2021;426:128880.

21. Venditti VJ, Simanek EE. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm. 2010;7:307–49.

22. Saterm AM, Skar M, Braaten Å, Brandt M. Camptothecin-catalyzed phospholipid hydrolysis in liposomes. Int J Pharmaceutics. 2005;288(1):73–80.

23. Zhang M, Chen X, Shen X. Charge-reversal nanocarriers: an emerging paradigm for smart cancer nanomedicine. J Control Release. 2020;319:46–62.

24. Jiang S, Cao Z. Ultralow-fouling, functionalizable, and hydrolyzable zwit-terionic materials and their derivatives for biological applications. Adv Mater. 2010;22:920–32.

25. Yin C, Tang Y, Li X, Yang Z, Li J, Li X, Huang W, Fan Q. A single composition architecture-based nanoprobe for ratiometric photoacoustic imaging of glutathione (GSH) in Living Mice. Small. 2018;14:1703400.

26. Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, Choinzonov E, Kzhyshkovska J. Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers. Front Oncol. 2020;10:566311.

27. Kulkarni A, Chandrasekar V, Natarajan SK, Ramesh A, Pandey P, Nigrud J, Bhattachar H, Ashok D, Ayak AJ, Sengupta S. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nature Biomedical Engineering. 2018;2:589–98.

28. Mahon OR, Browe DC, Gonzalez-Fernandez T, Pitacco P, Whelan IT, Von Euw S, Hobbs C, Nicolosi V, Cunningham KT, Mills KHG, et al. Nano-particle mediated M2 macrophage polarization enhances bone formation and MSC osteogenesis in an IL-10 dependent manner. Biomaterials. 2020;239:119833.

29. Xiao H, Guo Y, Li B, Li X, Wang Y, Han S, Cheng D, Shuai X. M2-like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IRKβ siRNA Induces M2-to-M1 repolarization for enhanced tumor penetration and chemo-immunotherapy. Adv Funct Mater. 2020;30:2003757.

30. Medzhivot R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–45.

31. Cao X, Cordova AF, Li L. Therapeutic interventions targeting innate immune receptors: a balancing act. Chem Rev. 2021;122:3414–58.

32. Roth GA, Piecek VCTM, Ou BS, Luo W, Pulemudri B, Appel EA. Designing spatial and temporal control of vaccine responses. Nat Rev Mater. 2021. https://doi.org/10.1038/s41578-021-00372-2

33. Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19:599–613.

34. Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, Bhutkar A, Wittrup KD, Spranger S. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2021;55:2038–23.

35. Buchwald ZS, Nasti TH, Lee J, Eberhardt CS, Wieland A, Im SJ, Lawson D, Curran W, Ahmed R, Khan MK. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J Immunother Cancer. 2020;8:e000867.

36. Li Q, Zhang D, Zhang J, Jiang Y, Song A, Li Z, Luan Y. A three-in-one immu-notherapy nanoweapon via cascade-amplifying cancer-immunity cycle against tumor metastasis, relapse, and postsurgical regrowth. Nano Lett. 2019;19:6647–57.

37. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nasimoto A, Itos S, Kaji M, Inamura H, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;266:277–83.

38. Fang H, Guo Z, Chen J, Lin L, Hu Y, Liu Y, Tian H, Chen X. Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. Nat Commun. 2021;12:6742.

39. Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, Wu X, Liu M, Wang S. Accumulation of fpox3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res. 2010;16:4105–12.

40. Schneider T, Kimpfler S, Warth A, Schnabel PA, Denemann H, Schaden-dorf D, Hoffmann H, Uimsayk V. Fqpo3+ Regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol. 2011;6:432–8.

41. Li Y, Wang Y, Huang G, Ma X, Zhou X, Gao J. Chaotrophic-anion-induced supramolecular self-assembly of ionic polymeric micelles. Angew Chem. 2014;53:8074–8.

42. Hostetter ML, Wingate JE, Zhong C-J, Harris JE, Vachet RW, Clark MR, Lon-dono JD, Green SJ, Stokes JJ, Wignall GD, et al. Alkanethiolate Gold Cluster Molecules with Core Diameters from 1.5 to 5.2 nm: Core and Monolayer Properties as a Function of Core Size. Langmuir. 1998;14:17–30.

43. Ma X, Bai S, Zhang X, Ma X, Jia D, Shi X, Shao J, Xue P, Kang Y, Xu Z. Enhanced tumor penetration and chemotherapy efficiency by covalent self-assembled nanomicelle responsive to tumor microenvironment. Biomacromol. 2019;20:2637–48.

44. Du H, Zhao S, Wang Y, Wang Z, Chen B, Yan Y, Yin Q, Liu D, Wan F, Zhang Q, et al. phl/Cathepsin B hierarchical-responsive nanonconjugates for enhanced tumor penetration and chemo-immunotherapy. Adv Funct Mater. 2020;30:2003757.

45. Zhang Z, Wang T, Yang R, Fu S, Guan L, Hou T, Mu W, Pang X, Liang S, Liu Y, et al. Small morph nanoparticles for deep tumor penetration via caveo-lae-mediated transcytosis. ACS Appl Mater Interfaces. 2020;12:38499–511.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.